ACE inhibitor (Enalapril 2.5-40mg/day (uptitrated as tolerated) vs placebo, severe heart failure

Polypharmacy icon of two pills

Study population:

Patients with severe heart failure  (NYHA class IV).

Co-morbidities included coronary heart disease, previous MI ,  hypertension and diabetes

Comments:

Mean age of patients was 70 years

Symptomatic improvement  was observed i.e. A significant improvement in NYHA classification

NB Patient numbers in the study were low (n=253)

 

Outcome Duration NNT Annualised NNT
Prevent one death (all cause) 188 days (mean followup)

7

3

References

The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. The New England Journal of Medicine. 1987; 316(23): 1429-1435